Vioxx Information
Vioxx information
from Merck & Co., Inc
Drug manufacturer's website containing information on Vioxx.
Vioxx information from the FDA
From the FDA's Center for Drug Evaluation and Research
Aug. 17, 2006: Merck Found Guilty of Failing To Warn Doctors About Vioxx
In a federal trial, a jury found that Merck failed to warn doctors about the risks of its painkiller Vioxx. It ruled that Merck must pay a retired FBI agent $50 million in compensatory damages, and another $1 million punitive damage award, for the heart attack he suffered in 2002 after taking the drug for several years.
August 2, 2006: California Jury Clears Merck in Vioxx Case
A Los Angeles jury found Vioxx manufacturer Merck & Co., Inc. not liable for an eldery man's heart problems, determining that the drugmaker did not wrongfully conceal information about the painkiller. The 71 year-old plaintiff began using Vioxx in 1999, and suffered a heart attack in 2001. Vioxx was withdrawn from the marketplace in 2004.
July 13, 2006: Merck Cleared in N.J. Vioxx Case
A jury in New Jersey cleared Vioxx manufacturer Merck & Co., Inc. of liability for the heart attack of a 68 year-old woman who had taken the painkiller for approximately two years, marking the fourth victory for Merck in seven completed court trials over the safety of Vioxx.
April 21, 2006: Family of Vioxx User Awarded $32M
A Texas jury found Vioxx manufacturer Merck & Co., Inc. liable for the fatal heart attack of a 71 year-old man who had used the painkiller for approximately one month prior to his death. The jury awarded $32 million ($7M as compensatory damages and $25M as punitive damages) to the man's family, after two days of deliberation.
April 11, 2006: N.J. Jury Awards $13.5M After Split Verdict in Vioxx Trial
A New Jersey jury awarded an additional $9 million as punitive damages for a former Vioxx patient, after finding a link between Vioxx use and the plaintiff's heart attack. On April 5th, 2006, the same jury found Merck & Co., Inc. liable for the 77 year-old plaintiff's illness, awarding him $4.5 million in compensatory damages based on the drug manufacturer's failure to properly warn of the painkiller's safety risk. The jury had cleared Merck of liability in connection with a second plaintiff's heart attack, finding that use of Vioxx was not a factor in the 60 year-old's illness.
February 17, 2006: Victory for Merck in First Federal Vioxx Trial
The jury in the first Vioxx trial in federal court cleared Vioxx manufacturer Merck & Co., Inc. of any liability in connection with the heart attack and death of a 53-year old Florida man who had taken the prescription painkiller for less than a month. A mistrial in the same case had been declared in December 2005, after the first jury was unable to reach a verdict.
December 12, 2005: Mistrial Declared in Federal Vioxx Trial
A mistrial has been declared in the first federal court trial over the safety of prescription painkiller Vioxx (pulled from the market in September 2004), after the jury was unable to reach a verdict despite three days of deliberations. The lawsuit was brought against Merck (manufacturer of the painkiller) by the widow of a man who died of a heart attack in 2001, after he had used Vioxx for approximately one month. The mistrial declaration means that the case can be re-tried before a new jury, or the parties can attempt to reach a settlement.
November 3, 2005: Merck Found Not Liable in Second Vioxx Trial
In a victory for Vioxx manufacturer Merck & Co., Inc., a New Jersey jury found the company not liable for a postal carrier's non-fatal heart attack in 2001. The plaintiff had claimed that his use of Vioxx (and Merck's alleged failure to warn Vioxx users of the painkiller's safety risks) caused a blood clot to form in his leg, resulting in a heart attack. The New Jersey jury disagreed, finding no such failure to warn, and insufficient proof of any fraud or misrepresentation committed by Merck.
August 19, 2005: $253.5M Verdict in First Vioxx Trial
A Texas jury awarded $253.5M to the widow of a Vioxx user, in the first trial among thousands of personal injury lawsuits seeking to hold drug manufacturer Merck & Co., Inc. liable for health problems caused by the painkiller. Vioxx was pulled from the worldwide market in September of 2004. Following the verdict, Merck & Co., Inc. announced that it intends to appeal the decision.
July 11, 2005: Jury Selection in First Vioxx Trial
Jury selection began in the first Vioxx trial in the U.S., as a pool of more than 100 possible jurors completed questionnaires in a Texas courtroom. The case, brought by the widow of a Vioxx user, is the first to go to trial among thousands of civil suits against Merck & Co., Inc., manufacturer of Vioxx. The painkiller was withdrawn from the market in September 2004, due to health dangers associated with its use, including risk of stroke and heart attack.
November 18, 2004: U.S. Senate Holds Vioxx Drug Safety Hearings
The U.S. Senate Finance Committee conducted a hearing called "FDA, Merck and Vioxx: Putting Patient Safety First," to consider allegations of mismanagement by the U.S. Food and Drug Administration and the Merck pharmaceutical company regarding the safety of Vioxx, a painkiller withdrawn from the worldwide drug market in September 2004.
More information:
- Testimony before the U.S. Senate Finance Committee
September 30, 2004: Vioxx Pulled from Drug Market Worldwide
Merck & Co., Inc., the manufacturer of Vioxx, announced a voluntary
withdrawal of the arthritis and pain relief drug from the worldwide drug
market, after results from a recent clinical trial indicated that Vioxx
users may have an increased risk of suffering a heart attack, stroke, or
other cardiovascular event. Merck's action was not ordered by the U.S.
Food and Drug Administration (FDA), but was initiated by Merck based on
its own findings from the clinical trial.
Approved by the FDA in 1999 for the treatment of osteoarthritis and
forms of acute pain (and later, for relief of rheumatoid arthritis),
Vioxx is a member of the "Cox-2 inhibitor" family of non-steroidal
anti-inflammatory drugs.
More information:
- Merck & Co. Inc. press release
- FDA Public Health Advisory on the safety of Vioxx
- FDA Questions and Answers on the Vioxx withdrawal